上海复星医药2005年第三季度报告（节录）_医药资讯

财务资料1、主要会计数据及财务指标币种:人民币本报告期末上年度期末本报告期末比上年度期末增减（％）总资产(元)5,658,218,438.905,170,502,559.879.43股东权益(不含少数股东权益)(元)2,408,964,354.922,304,105,035.774.55每股净资产(元)2.8962.7883.86调整后的每股净资产(元)2.8332.7662.42报告期年初至报告期期末本报告期比上年同期增减（％）经营活动产生的现金流量净额(元)135,901,860.72-9.85每股收益(元)0.06410.20986.83每股收益注1(元)0.06410.20986.83净资产收益率(%)2.2147.249减少0.28个百分点扣除非经常性损益后的净资产收益率(%)1.8526.225减少0.33个百分点非经常性损益项目金额(元)处置除公司产品外的其他资产产生的损益4,176,366.55各种形式的政府补贴4,903,170.86短期投资收益88,462.14扣除资产减值准备后的其他各项营业外收入、支出15,502,714.26合计24,670,713.79注1：如果报告期末至报告披露日，公司股本发生变化的，按新股本计算。2、利润表单位:元 币种:人民币 审计类型:未经审计项目合并母公司本期数(7-9月)上年同期数(7-9月)本期数(7-9月)上年同期数(7-9月)一、主营业务收入682,001,149.32693,509,370.341,882,355.713,238,447.27减：主营业务成本476,545,835.72439,053,293.491,873,105.543,231,471.84主营业务税金及附加3,690,666.585,520,745.170.00二、主营业务利润（亏损以“-”号填列）201,764,647.02248,935,331.689,250.176,975.43加：其他业务利润（亏损以“-”号填列）14,728,873.455,668,269.046,632,784.86511,739.00减:营业费用69,128,790.99114,079,696.240.000.00管理费用81,100,404.3190,279,509.658,601,900.125,565,877.73财务费用14,152,325.218,593,024.2011,785,678.834,828,932.19三、营业利润（亏损以“-”号填列）52,111,999.9641,651,370.63-13,745,543.92-9,876,095.49加：投资收益（损失以“-”号填列）32,671,859.4134,240,228.2566,857,921.5458,619,277.38补贴收入4,776,842.20964,661.010.000.00营业外收入3,469,336.675,549,016.160.000.00减：营业外支出2,037,771.072,841,133.150.000.00四、利润总额（亏损总额以“-”号填列）90,992,267.1779,564,142.9053,112,377.6248,743,181.89减：所得税8,873,344.2813,948,645.46-224,733.520.00减：少数股东损益28,781,811.7516,872,315.550.00加：未确认投资损失(合并报表填列)0.000.00五、净利润（亏损以“-”号填列）53,337,111.1448,743,181.8953,337,111.1448,743,181.89单位:元 币种:人民币 审计类型:未经审计项目合并母公司本期数(1-9月)上年同期数(1-9月)本期数(1-9月)上年同期数(1-9月)一、主营业务收入2,148,873,798.431,976,978,521.059,055,633.116,627,100.07减：主营业务成本1,474,700,006.151,336,562,513.278,884,960.536,594,075.09主营业务税金及附加11,970,910.9213,355,960.330.00480,009.88二、主营业务利润（亏损以“-”号填列）662,202,881.36627,060,047.45170,672.58-446,984.90加：其他业务利润（亏损以“-”号填列）37,896,832.9222,454,672.6113,841,484.995,963,117.84减:营业费用285,317,262.45278,699,562.720.000.00管理费用238,359,579.36233,295,471.2123,989,013.6517,554,635.54财务费用30,797,621.5717,041,979.5526,316,998.8310,879,616.36三、营业利润（亏损以“-”号填列）145,625,250.90120,477,706.58-36,293,854.91-22,918,118.96加：投资收益（损失以“-”号填列）108,834,342.80128,080,279.69210,687,363.95192,049,114.99补贴收入6,394,911.655,696,376.110.000.00营业外收入38,154,325.486,888,599.870.000.00减：营业外支出2,768,002.734,251,126.490.0025,977.09四、利润总额（亏损总额以“-”号填列）296,240,828.10256,891,835.76174,393,509.04169,105,018.94减：所得税37,281,560.5430,049,705.47-224,733.52-1,967,910.54减：少数股东损益84,360,019.3055,769,200.81加：未确认投资损失(合并报表填列)18,994.30五、净利润（亏损以“-”号填列）174,618,242.56171,072,929.48174,618,242.56171,072,929.48 详见《上海复星医药（集团）股份有限公司2005年第三季度报告》（据“上海证券交易所”；医药网整理，严禁转载） 医药网新闻